2013-01-21 15:28:12 - Fast Market Research recommends "Fluvirin (Seasonal Influenza Vaccine) Forecast and Market Analysis" from GlobalData, now available

GlobalData has released its new PharmaPoint Drug Evaluation report, "Fluvirin (Seasonal Influenza Vaccine) Forecast and Market Analysis". Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers

that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.


Full Report Details at
- www.fastmr.com/prod/529882_fluvirin_seasonal_influenza_vaccine_f ..


Fluvirin is a trivalent, inactivated influenza vaccine designed to immunize recipients against seasonal influenza infections. The vaccine is prepared from influenza vaccine viruses that are propagated in embryonated chicken eggs. Each viral strain is harvested via centrifugation and inactivated with beta-propiolactone. The viral surface antigens (i.e., hemagglutinin, neuraminidase) are then purified via centrifugation. Fluvirin is administered via intramuscular injection, where the viral antigens elicit an immune response that helps protect the recipient from subsequent influenza infection. Fluvirin is marketed in the US and UK by Novartis.

Scope

* Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Fluvirin including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Fluvirin from 2012 to 2022.
* Sales information covered for the US, and the UK.

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Fluvirin performance
* Obtain sales forecast for Fluvirin from 2012 to 2022 in the US, and the UK.

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Influenza Vaccination Policy
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profile - Fluvirin
5.3.1 Overview
5.3.2 Efficacy
5.3.3 Safety
5.3.4 SWOT Analysis
5.3.5 Forecast
6 Appendix
6.1 Abbreviations
6.2 Bibliography
6.3 Methodology
6.4 Forecasting Methodology
6.4.1 Vaccine Coverage
6.4.2 Influenza Vaccine Tender System Assumptions
6.4.3 General Pricing Assumptions
6.4.4 Individual Vaccine Assumptions
6.5 Physicians and Specialists Included in this Study
6.6 Primary Research - Prescriber Survey
6.7 About the Authors
6.7.1 Authors
6.7.2 Global Head of Healthcare
6.8 About GlobalData
6.9 Contact Us
6.10 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Most Administered Influenza Vaccines by Country in the Global Markets, 2012
Table 5: Leading Influenza Vaccines, 2012
Table 6: Product Profile - Fluvirin
Table 7: Immunogenicity of Agrippal and Fluvirin
Table 8: Fluvirin SWOT Analysis, 2012
Table 9: Global Sales Forecasts ($m) for Fluvirin, 2012-2022
Table 10: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: Influenza Virus Structure

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.